World News

Showing posts with label article. Show all posts
Showing posts with label article. Show all posts

Offsite Backup: Benefits And Threats Unveiled

Tuesday, June 7, 2011

Good backup habits are essential to everyone who uses a computer with important information. It takes just a few accidental clicks of the mouse - or worse, one isolated hardware failure - and valuable data can be lost.

One dilemma for backup users is often where to put their backups. Storing them on your own hard drive is obviously not the best option. Not everyone wants to split their backups into several parts using a CD or DVD burner, and an external hard drive isn't a ...

Good backup habits are essential to everyone who uses a computer with important information. It takes just a few accidental clicks of the mouse - or worse, one isolated hardware failure - and valuable data can be lost.

One dilemma for backup users is often where to put their backups. Storing them on your own hard drive is obviously not the best option. Not everyone wants to split their backups into several parts using a CD or DVD burner, and an external hard drive isn't a standard fixture on many users' desks.

One solution to this problem, and a solution that can save a lot of time and effort, is offsite or remote backup. Backing up to a computer offsite means that your data will end up on a different drive or computer, which basically halves the chance of catastrophic loss. This can be especially useful for office users. If your company has several locations, backing up over a network to a computer situated elsewhere can provide a contingency in case of a power surge, fire, employee misuse or plain user error.

Offsite backup over a network:

Most backup programs support network backup, and the way to use this is simple. Local Area Networks (LAN) and Wide Area Networks (WAN) usually feature "network drives", which appear to your computer as an ordinary drive. They often have names like M:, N:, O: and so on. Depending on permissions set up by the people administrating your network, you may be able to write to certain drives but not read from them, or you may not be able to change or delete data once it's written. These are common situations, but they should not affect the way you back up.

Once you have found a suitable location for your data - your administrator will be able to help you with this - backing up can be as easy and fast as with an external drive.

Select the appropriate drive and the data you want to save and that's it. Even though a network connection is usually not as fast as a local cable, this is just a matter of waiting. Most programs allow you to set a backup timetable, which is a great way to take the effort out of backup. If you leave your computer on at night, then setting an incremental backup every second day at 2am, for example, ensures the safety of your data. A possible disadvantage here is that if your network goes down, you might not be able to get your data back for some time. Laptop users might not always be connected to the network at the scheduled backup time, defeating the purpose entirely.

Offsite backup through FTP:

Another form of offsite backup uses a File Transfer Protocol (FTP) server over the Internet. FTP is traditionally used to move large files online and can reliably transfer any files of any size.

To access data stored on an FTP server, you can use your backup program, a special FTP client or just a regular web browser. While there are two "types" of FTP server, public and private, you will almost certainly be using a private server, which requires a password to access your data. Advantages of this method include that you can view the files stored on the FTP any time you wish using any FTP client, mobile users can back up from anywhere in the world with an Internet connection, and FTP backup can be somewhat cheaper than a specialised remote backup service.

The main disadvantage inherent in this method is data security. The FTP protocol is not secure, and even a private FTP account does not ensure the security of your files; it only protects access to the FTP server. Anyone with access to your username and password has access to your data. Added to this, unless you take steps to protect it, your data will be unencrypted as it travels to the FTP server, and could possibly be intercepted. We recommend that you encrypt your files before sending them.

One option is to store your data in a standard password-protected ZIP archive. This is a quick method that allows you to extract your files on any computer using any ZIP client. There are ZIP programs that provide tighter security by applying stronger encryption algorithms, like AES or Blowfish. This increases the security of your data, but to decrypt your files you may need to use the program that encrypted and backed them up.

To obtain access to a private FTP server, find a good hosting company (try searching with Google) and compare based on price and location - companies with servers based in your country will usually be faster. Beware that your Internet Service Provider (ISP) might charge you for the data you send, so you may wish to make incremental backups over FTP, which only backup what was changed since your last backup.

Specialised offsite backup:

Another form of offsite backup is the use of a special server provided by the company that makes your backup solution. They usually use their own protocols to encrypt and transfer your data, and a special program on their end to store it. You may have some issues using such services if you're behind a firewall, as some of these services use non-standard Internet Protocol (IP) ports.

Offsite backup services are usually paid for by the month, by the amount of data transferred or both. They can be quite expensive, especially if you wish to back up a lot of data, or use the service over a long period of time. As with FTP servers, you may also be charged by your ISP to send your data.

Still, offsite backup services represent a convenient method, as they'll usually be built right into backup programs that support the feature. Ensure the credentials of the company you're dealing with, as an offsite backup service is pointless if your backup company happens to shut up shop or "can't find" your data - just as your hard drive fails.
READ MORE - Offsite Backup: Benefits And Threats Unveiled

Beauchamp MC

Wednesday, May 18, 2011

Beauchamp MC, Knafo A, Yasmeen A, Carboni JM, Gottardis MM, Pollak MN, Gotlieb WH. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecol Oncol. 2009;155 (2:193–198.
Beck R, Verrax J, Dejeans N, Taper H, Calderon PB. Menadione reduction by pharmacological doses of ascorbate induces an oxidative stress that kills breast cancer cells. Int J Toxicol. 2009;28:33–42. [PubMed]
Boersma AWM, Nooter K, Oostrum RG, Stoter G. Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in Chinese Hamster ovary cell cultures treated with cisplatin. Cytometry. 1996;24:123–130. [PubMed]
Boya P, Andreau K, Poncet D, Zamzami N, Perfettini JL, Metivier D, Ojcius DM, Jäättelä M, Kroemer G. Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med. 2003;197:1323–1934. [PMC free article] [PubMed]
Buc-Calderon P, Praet M, Ruysschaert JM, Roberfroid M. Increasing therapeutic effect and reducing toxicity of doxorubicin by N-acyl dehydroalanines. Eur J Cancer Clin Oncol. 1989;25:679–685. [PubMed]
Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res. 1987;47:943–946. [PubMed]
Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, Choyke PL, Pooput C, Kirk KL, Buettner GR, Levine M. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA. 2007;104:8749–8754.
Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA. 2005;102:13604–13609.
D'Alessio M, De Nicola M, Coppola S, Gualandi G, Pugliese L, Cerella C, Cristofanon S, Civitareale P, Ciriolo MR, Bergamaschi A, Magrini A, Ghibelli L. Oxidative Bax dimerization promotes its translocation to mitochondria independently of apoptosis. FASEB J. 2005;19:1504–1506. [PubMed]
De Loecker W, Janssens J, Bonte J, Taper HS. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. II. Synergism with combined chemotherapy action. Anticancer Res. 1993;13:103–106. [PubMed]
Dong LF, Freeman R, Liu J, Zobalova R, Marin-Hernandez A, Stantic M, Rohlena J, Valis K, Rodriguez-Enriquez S, Butcher B, Goodwin J, Brunk UT, Witting PK, Moreno-Sanchez R, Scheffler IE, Ralph SJ, Neuzil J. Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II. Clin Cancer Res. 2009;15:1593–1600. [PubMed]
Dong LF, Low P, Dyason J, Wang XF, Prochazka L, Witting PK, Freeman R, Swettenham E, Valis K, Liu J, Zobalova R, Turanek J, Spitz DR, Domann FE, Scheffler IE, Ralph SJ, Neuzil J. α-Tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene. 2008;27:4324–4335. [PMC free article] [PubMed]
Eichhorn ME, Ischenko I, Luedemann S, Strieth S, Papyan A, Werner A, Bohnenkamp H, Guenzi E, Preissler G, Michaelis U, Jauch KW, Bruns CJ, Dellian M. Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer. 2010;126 (5:1235–1245. [PubMed]
Fantin VR, Leder P. Mitochondriotoxic compounds for cancer therapy. Oncogene. 2006;25:4787–4797. [PubMed]
Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them. Trends Cell Biol. 2008;18:165–173. [PubMed]
Gilloteaux J, Jamison JM, Arnold D, Ervin E, Eckroat L, Docherty JJ, Neal D, Summers JL. Cancer cell necrosis by autoschizis: synergism of antitumor activity of vitamin C: vitamin K3 on human bladder carcinoma T24 cells. Scanning. 1998;20:564–575. [PubMed]
Gilloteaux J, Jamison JM, Arnold D, Taper HS, Summers JL. Ultrastructural aspects of autoschizis: a new cancer cell death induced by the synergistic action of ascorbate/menadione on human bladder carcinoma cells. Ultrastruct Pathol. 2001;25:183–192. [PubMed]
Gilloteaux J, Jamison JM, Neal DR, Summers JL. Cell death by autoschizis in TRAMP prostate carcinoma cells as a result of treatment by ascorbate: menadione combination. Ultrastruct Pathol. 2005;29:221–235. [PubMed]
Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4:682–690. [PubMed]
Jamison JM, Gilloteaux J, Venugopal M, Koch JA, Sowick C, Shah R, Summers JL. Flow cytometric and ultrastructural aspects of the synergistic antitumor activity of vitamin C-vitamin K3 combinations against human prostatic carcinoma cells. Tissue Cell. 1996;28:687–701. [PubMed]
Jamison JM, Gilloteaux J, Taper HS, Buc Calderon P, Perlaky L, Thiry M. The in vitro and in vivo antitumor activity of vitamin C:K3 combinations against prostate cancer Trends in Prostate Cancer Research 2005. Nova Science Publishers: Hauppauge, NY; 189–236.Lucas JL (ed)
Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res. 2005;65:10524–10535. [PubMed]
Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov. 2005;4:71–78. [PubMed]
Kitano H. Robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov. 2007;6:202–210. [PubMed]
Koch N, van Driel IR, Gleeson PA. Hijacking a chaperone: manipulation of the MHC class II presentation pathway. Immunol Today. 2000;21:546–550. [PubMed]
Lehár J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, Rickles RJ, Short GF, III, Staunton JE, Jin X, Lee MS, Zimmermann GR, Borisy AA. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009;27:659–666. [PMC free article] [PubMed]
Lu W, Dong Z, Donawho C, Fidler IJ. Specific immunotherapy against occult cancer metastases. Int J Cancer. 2002;100:480–485. [PubMed]
Mannick JB, Schonhoff C, Papeta N, Ghafourifar P, Szibor M, Fang K, Gaston B. S-nitrosylation of mitochondrial caspases. J Cell Biol. 2001;154:1111–1116. [PMC free article] [PubMed]
Neuzil J, Dong LF, Ramanathapuram L, Hahn T, Chladova M, Wang XF, Zobalova R, Prochazka L, Gold M, Freeman RE, Turanek J, Akporiaye ET, Dyason J, Ralph SJ. Vitamin E analogues: a novel group of mitocans, anti-cancer agents that act by targeting mitochondria. Mol Aspects Med. 2007b;28:607–645. [PubMed]
Neuzil J, Svensson I, Weber T, Weber C, Brunk UT. α-Tocopheryl succinate-induced apoptosis in Jurkat T cells involves caspase-3 activation, and both lysosomal and mitochondrial destabilisation. FEBS Lett. 1999;445:295–300. [PubMed]
Neuzil J, Tomasetti M, Mellick AS, Alleva R, Salvatore BA, Birringer M, Fariss MW. Vitamin E analogues: a new class of inducers of apoptosis with selective anti-cancer effects. Curr Cancer Drug Targets. 2004;4:355–372. [PubMed]
Neuzil J, Tomasetti M, Zhao Y, Dong LF, Birringer M, Wang XF, Low P, Wu K, Salvatore BA, Ralph SJ. Vitamin E analogs, a novel group of ‘mitocans' as anticancer agents: the importance of being redox-silent. Mol Pharmacol. 2007a;71:1185–1199. [PubMed]
Neuzil J, Wang XF, Dong LF, Low P, Ralph SJ. Molecular mechanism of ′mitocan′-induced apoptosis in cancer cells epitomizes the multiple roles of reactive oxygen species and Bcl-2 family proteins. FEBS Lett. 2006;580:5125–5129. [PubMed]
Neuzil J, Weber T, Gellert N, Weber C. Selective cancer cell killing by α-tocopheryl succinate. Br J Cancer. 2001a;84:87–89. [PMC free article] [PubMed]
Neuzil J, Weber T, Schröder A, Lu M, Ostermann G, Gellert N, Mayne GC, Olejnicka B, Nègre-Salvayre A, Sticha M, Coffey RJ, Weber C. Induction of apoptosis in cancer cells by α-tocopheryl succinate: Molecular pathways and structural requirements. FASEB J. 2001b;15:403–415. [PubMed]
Neuzil J, Zhao M, Ostermann G, Sticha M, Gellert N, Weber C, Eaton JW, Brunk UT. α-Tocopheryl succinate, an agent with in vivo anti-tumour activity, induces apoptosis by causing lysosomal instability. Biochem J. 2002;362:709–715. [PMC free article] [PubMed]
Ogawa M, Nakai S, Deguchi A, Nonomura T, Masaki T, Uchida N, Yoshiji H, Kuriyama S. Vitamins K2, K3 and K5 exert antitumor effects on established colorectal cancer in mice by inducing apoptotic death of tumor cells. Int J Oncol. 2007;31:323–331. [PubMed]
Rhee SG. Cell signaling. H2O2, a necessary evil for cell signaling. Science. 2006;312:1882–1883. [PubMed]
Roberts WK, Livingston PO, Agus DB, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood. 2002;99:3748–3755. [PubMed]
Sakagami H, Satoh K. Modulating factors of radical intensity and cytotoxic activity of ascorbate. Anticancer Res. 1997;17:3513–3520. [PubMed]
Stapelberg M, Gellert N, Swettenham E, Tomasetti M, Witting PK, Procopio A, Neuzil J. α-Tocopheryl succinate inhibits malignant mesothelioma by disrupting the FGF autocrine loop: the role of oxidative stress. J Biol Chem. 2005;280:25369–25376. [PubMed]
Stelling J, Sauer U, Szallasi Z, Doyle FJ, III, Doyle J. Robustness of cellular functions. Cell. 2004;118:675–685. [PubMed]
Taper HS, Roberfroid M. Non-toxic sensitization of cancer chemotherapy by combined vitamin C and K3 pretreatment in a mouse tumor resistant to oncovin. Anticancer Res. 1992;12:1651–1654. [PubMed]
Taper HS, Jamison JM, Gilloteaux J, Gwin CA, Gordon T, Summers JL. In vivo reactivation of DNases in implanted human prostate tumors after administration of a vitamin C/K(3) combination. J Histochem Cytochem. 2001;49:109–120. [PubMed]
Tareen B, Summers JL, Jamison JM, Neal DR, McGuire K, Gerson L, Diokno A. A 12 week, open label, phase I/IIa study using apatone for the treatment of prostate cancer patients who have failed standard therapy. Int J Med Sci. 2008;5:62–67. [PMC free article] [PubMed]
Tomasetti M, Alleva R, Borghi B, Collins AR. In vivo supplementation with coenzyme Q10 enhances the recovery of human lymphocytes from oxidative DNA damage. FASEB J. 2001;15:1425–1427. [PubMed]
Tomasetti M, Rippo MR, Alleva R, Moretti S, Andera L, Neuzil J, Procopio A. α-Tocopheryl succinate and TRAIL selectively synergise in apoptosis induction in human malignant mesothelioma cells. Br J Cancer. 2004;90:1644–1653. [PMC free article] [PubMed]
Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach. Nat Rev Drug Discov. 2009;8:579–591. [PubMed]
Uwagawa T, Chiao PJ, Gocho T, Hirohara S, Misawa T, Yanaga K. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-κB activation. Anticancer Res. 2009;29:3173–3178. [PubMed]
Vassalle C, Boni C, Di Cecco P, Ndreu R, Zucchelli GC. Automation and validation of a fast method for the assessment of in vivo oxidative stress levels. Clin Chem Lab Med. 2006;44:1372–1375. [PubMed]
Venugopal M, Jamison JM, Gilloteaux J, Koch JA, Summers M, Giammar D, Sowick C, Summers JL. Synergistic antitumor activity of vitamins C and K3 on human urologic tumor cell lines. Life Sci. 1996;59:1389–1400. [PubMed]
Verrax J, Delvaux M, Beghein N, Taper H, Gallez B, Buc Calderon P. Enhancement of quinone redox cycling by ascorbate induces a caspase-3 independent cell death in human leukaemia cells. An in vitro comparative study. Free Radic Res. 2005;39:649–657. [PubMed]
Wang XF, Birringer M, Dong LF, Veprek P, Low P, Swettenham E, Stantic M, Yuan LH, Zobalova R, Wu K, Ralph SJ, Ledvina M, Neuzil J. A peptide adduct of vitamin E succinate targets breast cancer cells with high erbB2 expression. Cancer Res. 2007;67:3337–3344. [PubMed]
Zahorowska B, Crowe PJ, Yang JL. Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. J Cancer Res Clin Oncol. 2009;135:1137–1148. [PubMed]
Zamzami N, Marzo I, Susin SA, Brenner C, Larochette N, Marchetti P, Reed J, Kofler R, Kroemer G. The thiol crosslinking agent diamide overcomes the apoptosis-inhibitory effect of Bcl-2 by enforcing mitochondrial permeability transition. Oncogene. 1998;16:1055–1063. [PubMed]
Zhu Z, Haegele AD, Thompson HJ. Effect of caloric restriction on pre-malignant and malignant stages of mammary carcinogenesis. Carcinogenesis. 1997;18:1007–1012
READ MORE - Beauchamp MC